Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Non-Small-Cell Lung 38 Neoplasms 19 Breast Neoplasms 9 Head and Neck Neoplasms 5 Colorectal Neoplasms 3 Neoplasm Metastasis 2 Carcinoma, Squamous Cell 2 Adenocarcinoma 2 Urologic Neoplasms 1 Stomach Neoplasms 1 Squamous Non-small Cell Lung Cancer 1 Solid Tumors 1 Rhabdomyosarcoma 1 Prostatic Neoplasms 1 Pancreatic Neoplasms 1 Neuroectodermal Tumors 1 NSCLC Harboring NRG1 Fusion 1 Lung Neoplasms 1 Glioma 1 Glioblastoma 1 Colonic Neoplasms 1 Advanced Solid Tumors 1

Interventions

Gemcitabine 7 Cisplatin 5 pembrolizumab 4 enfortumab vedotin 4 Mitomycin 4 Trastuzumab 3 Pemetrexed 3 Carboplatin 3 dodecyl maltoside 2 atezolizumab 2 Sunitinib 2 vinflunine 1 valrubicin 1 tucatinib 1 palbociclib 1 niraparib 1 motexafin gadolinium 1 cabozantinib 1 avelumab 1 apatorsen 1 Water 1 VMBP protocol 1 Standard of Care 1 Radiation Dose Hypofractionation 1 Nivolumab 1 Neoadjuvant Therapy 1 Immunoglobulins, Intravenous 1 Gels 1 GSK-3326595 1 Fulvestrant 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Urologic Neoplasms × Afatinib × Clear all

NCT02780687 2020-11-18

LUX-Bladder 1

Boehringer Ingelheim

Phase 2 Completed

42 enrolled 16 charts

Urologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡